Orpharma

What Orpharma does

Orpharma Pty Ltd is a privately held Australian specialty pharmaceutical company founded in 2013 and headquartered in Melbourne, operating exclusively in paediatric, orphan, and niche medicines. The company markets and distributes a portfolio of products targeting rare inherited metabolic disorders, including phenylketonuria (PKU), urea cycle disorders, tyrosinaemia (TYR), homocystinuria (HCU), maple syrup urine disease (MSUD), as well as Ménière's disease and inflammatory bowel disease. Core offerings include medical nutrition products such as the PKU range (PKU Go, PKU Easy Shake & Go, PKU Easy Liquid, PKU Easy Microtabs, PKU Baby, PKU Easy Tablets), disease-specific amino acid substitutes (TYR Easy, HCU Easy, MSUD Easy, Citrulline Easy), the orphan-designated taste-masked formulation Pheburane (sodium phenylbutyrate), the antisecretory factor products SPC Flakes and Salovum, and the Promin low-protein food range.

The company's product portfolio is sourced through exclusive distribution agreements with international partners including Lucane Pharma (France) for Pheburane, POA Pharma Scandinavia AB for antisecretory factor products, Cycle Pharmaceuticals for an orphan metabolic drug, and Neolutions for niche products. Orpharma does not develop or manufacture drugs internally; its value proposition lies in regulatory navigation, market access, and channel build-out across Australia, New Zealand, and South East Asia. The company has secured multiple TGA orphan drug designations, MEDSAFE approval in New Zealand, and listings on the Pharmaceutical Benefits Scheme (PBS) and Life Saving Drugs Program (LSDP), which underpin government reimbursement for several flagship products.

Revenue is generated primarily through pharmaceutical product sales to pharmacies and hospitals under prescription, supplemented by home delivery to registered patients and direct-to-consumer e-commerce for the Promin low-protein food range via a Shopify storefront. Customers are healthcare professionals (dietitians, medical doctors) who prescribe and recommend products, with end users being patients with rare metabolic and niche conditions. The company has remained small, with 1-10 employees and no disclosed external funding rounds, operating as a profitable or cash-flow-funded specialty distribution business.

Name

Orpharma

Legal name

Orpharma Pty Ltd

Website

https://orpharma.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Orpharma is an Australian specialty pharmaceutical company that markets and distributes paediatric, orphan, and niche medicines for rare metabolic disorders (PKU, urea cycle disorders, tyrosinaemia, MSUD, HCU) across Australia, New Zealand, and South East Asia under exclusive distribution agreements and PBS/LSDP reimbursement.

Ownership category

akta.pro rank

Product category

Orphan Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Medical Nutrition & Meal Replacement (RTD, Bars, Powders) (CRADAGAN)

akta.pro secondary industries

Protein & Meal-Replacement Beverage Production (RTD Shakes) (AFAFAFAD), Medical & Clinical Nutrition Beverage Production (Oral Nutritional Supplements) (AFAFAFAJ), Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium) (AFAKAJAD), Specialty & Medical Infant Formula (Hypoallergenic, Lactose-Free, Metabolic) (CRADAEAB)

Keywords

• Orphan pharmaceuticals
• Medical nutrition products
• Metabolic disorder treatments
• Low protein foods
• Paediatric medicines

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary and distributed pharmaceutical products including orphan drugs, medical nutrition products, and paediatric medicines through pharmacy and hospital channels.
2. Marketing and Distribution Rights: Orpharma holds marketing rights to various products in Australia, New Zealand, and South East Asia regions, generating revenue through distribution agreements with global pharmaceutical partners.
3. E-commerce Product Sales: Direct consumer sales through own Shopify storefront for low protein foods (Promin range) and antisecretory products.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Orpharma develops, distributes, and markets pharmaceutical products, medical nutrition formulations, and orphan drugs for the dietary management and treatment of rare metabolic disorders including phenylketonuria (PKU), urea cycle disorders, tyrosinaemia, homocystinuria, and maple syrup urine disease, as well as Ménière's disease and inflammatory bowel disease. Its offering includes amino-acid-based protein substitutes, taste-masked orphan drugs, antisecretory factor products, and the Promin low-protein food range, sold primarily through pharmacies, hospital channels, and home delivery.

Product overview

Orpharma is an Australian pharmaceutical company offering a diverse portfolio of pharmaceutical products and medical nutrition foods. The product portfolio includes: (1) Medical Nutrition products for dietary management of inherited metabolic disorders including PKU (Phenylketonuria), TYR (Tyrosinaemia), HCU (Homocystinuria), MSUD (Maple Syrup Urine Disease), and Urea Cycle Disorders - these include PKU Go, PKU Easy Shake & Go, PKU Easy Liquid, PKU Easy Microtabs, PKU Easy Tablets, PKU Baby, TYR Easy Tablets, TYR Easy Shake & Go, HCU Easy Tablets, MSUD Easy Tablets, Citrulline Easy, and SPC Flakes; (2) Orphan Pharmaceuticals including Pheburane (sodium phenylbutyrate) for Urea Cycle Disorders; (3) Low Protein Foods under the Promin brand including breakfast items, pasta, snacks, and baking products for patients with metabolic disorders; (4) Paediatric products available under SAS; and (5) Specialised devices. The products are available through pharmacies or home delivery service.

Differentiator

Problem solved

Functional benefit

Products and services

• Pheburane (sodium phenylbutyrate granules) Taste-masked formulation of sodium phenylbutyrate for treatment of Urea Cycle Disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, and argininosuccinate synthetase. Orphan-designated by TGA. For patients with UCDs requiring nitrogen-scavenging therapy.
• NITYR (nitisinone tablets 2mg, 5mg, 10mg) Nitisinone tablets for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine. Listed on the Life Saving Drugs Program.
• PKU Go Phenylalanine-free amino acid powder for children aged 1 to 10 with PKU. Dissolved in water and consumed as a gel or liquid drink. Pack size: 30 x 20g sachets.
• PKU Baby Ready-to-drink phenylalanine-free beverage with essential and non-essential amino acids, carbohydrates, fat, vitamins, minerals, trace elements, and LCP for dietary management of infants with PKU from birth to 1 year.
• PKU Easy Shake & Go Flavoured ready-to-drink phenylalanine-free protein substitute containing essential and non-essential amino acids, carbohydrate, vitamins, minerals and trace elements. Available in unflavoured or orange flavour. For PKU patients aged 3 and older.
• PKU Easy Liquid Ready-to-drink phenylalanine-free amino acid, vitamin, and mineral source for patients aged 3 years and over with PKU. Available in orange/citrus and berries flavours.
• PKU Easy Microtabs Small coated microtabs with concentrated amino acids for dietary treatment of PKU. Swallowed with liquid or eaten with jam or fruit puree; no bad taste or smell. For patients 3 years and older. PKU Easy Microtabs Plus listed on PBS April 2025.
• PKU Easy Tablets Phenylalanine-free protein substitute tablet containing essential and non-essential amino acids for dietary management of PKU in patients aged 3 and older. PBS-listed.
• TYR Easy Tablets Tyrosine and phenylalanine-free protein substitute tablet containing essential and non-essential amino acids for dietary management of tyrosinaemia in patients aged 3 and older. PBS-listed.
• TYR Easy Shake & Go Flavoured ready-to-drink phenylalanine and tyrosine-free protein substitute containing essential and non-essential amino acids, carbohydrate, vitamins, minerals and trace elements. Available in orange flavour. For dietary management of TYR in patients aged 3 and older.
• HCU Easy Tablets Methionine-free protein substitute tablet containing essential and non-essential amino acids for dietary management of homocystinuria (HCU) in patients aged 3 and older. PBS-listed.
• MSUD Easy Tablets Leucine, isoleucine and valine-free protein substitute tablet containing essential and non-essential amino acids for dietary management of MSUD in patients aged 3 and older. PBS-listed.
• Citrulline Easy L-citrulline amino acid tablets (1 gram per tablet) for dietary management of patients with inherited metabolic conditions, especially urea cycle disorders. For patients aged 3 and older.
• SPC Flakes Dietary food for special medical purposes that induces antisecretory factor expression. Used for dietary management of Ménière's disease, inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diarrhea), and mastitis.
• Promin Low Protein Food Range High quality, low protein foods suitable for patients with inherited metabolic disorders including PKU, MSUD, tyrosinaemia, homocystinuria, and urea cycle disorders. Range includes breakfasts, pasta, snacks, meal pots, baking mixes, and burger/sausage mixes.

Quantifiable outcome

• PKU Easy Microtabs Plus listed on Pharmaceutical Benefits Scheme (PBS) April 2025 for dietary management of proven Phenylketonuria
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Cycle PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 17 November 2016Orpharma signed a distribution agreement with Cycle Pharmaceuticals for an orphan drug developed for the treatment of a metabolic condition. Orpharma has the marketing rights to the products in Australia and New Zealand.
• POA Pharma Scandinavia ABcoreChannel Partner/ Reseller/ Distributor · 6 November 2015Distribution agreement for products containing Antisecretory Factor developed to treat Crohn's disease, short bowel syndrome, and Ménière's disease. Products include SPC Flakes and Salovum.
• Lucane PharmacoreChannel Partner/ Reseller/ Distributor · 15 April 2014Exclusive distribution agreement for Pheburane (sodium phenylbutyrate granules) covering Australian and New Zealand territories. Pheburane is an improved formulation of sodium phenylbutyrate developed for treatment of Urea Cycle Disorders. Partnership expanded in October 2016 to include more products for treatment of various metabolic conditions.
• NeolutionsminorChannel Partner/ Reseller/ Distributor · 31 May 2013Distribution deal for a range of niche products with marketing rights in Australia, New Zealand, and South East Asia.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Nutricia (Danone Specialized Nutrition): Global leader in medical nutrition for inborn errors of metabolism including PKU, MSUD, TYR, HCU, and UCDs. Directly competes with Orpharma's PKU Easy, Citrulline Easy, and TYR/HCU/MSUD product lines across overlapping geographies.
• Vitaflo (Nestlé Health Science): Specialist in metabolic disorder nutrition and phenylketonuria products. Competes head-to-head with Orpharma's PKU range in Australia and New Zealand, including protein substitutes and age-specific formulations.
• Dr. Schär: Specialist in low-protein and special-dietary-needs foods for PKU and other inherited metabolic disorders. Directly comparable to Orpharma's Promin low-protein food range and competes in adjacent patient channels.

Broad incumbents

• Mead Johnson (Reckitt): Major infant nutrition and specialty formula manufacturer. Competes in the metabolic infant formula space (e.g., PKU Baby equivalents) and is a broad incumbent with global scale far exceeding Orpharma's distribution model.
• Abbott Nutrition: Diversified medical and consumer nutrition business with metabolic disorder product lines. Competes with Orpharma across medical nutrition, RTD formulations, and pediatric feeding, particularly in hospital and pharmacy channels.
• BioMarin Pharmaceutical: Specialty rare disease biopharma with approved and pipeline metabolic disorder therapies (e.g., Palynziq for PKU). Operates in the same patient population and competes for prescriber mindshare, though at a different point in the treatment paradigm.
• Swedish Orphan Biovitrum (SOBI): Rare disease specialty pharmaceutical company with metabolic and orphan drug franchises across Europe and other markets. Comparable business model of focusing on niche, high-unmet-need therapeutics via distribution partnerships.
• Recordati Rare Diseases: Specialty pharma division focused on rare and orphan diseases with established metabolic disorder treatments. Competes for hospital and specialty pharmacy channels serving the same prescriber base as Orpharma.

Emerging players

• Cambrooke Therapeutics: Specialty nutrition company focused on PKU and other inherited metabolic disorders, offering both medical foods and pharmaceutical-grade protein substitutes. Comparable niche focus and patient base to Orpharma's metabolic portfolio.

Regional players

• Phebra (Australian specialty pharma): Australian specialty pharmaceutical company focused on niche, critical, and rare disease medicines. Comparable ANZ-focused distribution-led model serving hospitals, with overlapping therapeutic areas and regulatory pathway experience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/3169109

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orpharma